The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot.

The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

More importantly, working with the U.S. government positions Moderna to be one of the preferred providers of vaccines in the event of a larger influenza outbreak during the next flu season.

The boosters are so-called “bivalent vaccines,” which are designed ... can be administered to people 12 and older, while Moderna Inc.’s Omicron booster is authorized for those 18 and older.

As norovirus cases increase across the U.S., Moderna is conducting a phase 3 trial with 25,000 participants to test its experimental vaccine, CNBC reported. The vaccine manufacturer is recruiting ...

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

Note: This page is no longer being updated as of April 15, 2022 because our data provider has stopped collecting vaccination data. Current data can be found on the Public Health Agency of Canada ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...